ImmunityBio 배당 및 자사주 매입

배당 기준 점검 0/6

ImmunityBio 배당금을 지급한 기록이 없습니다.

핵심 정보

n/a

배당 수익률

-6.8%

자사주 매입 수익률

총 주주 수익률	-6.8%
미래 배당 수익률	n/a
배당 성장률	n/a
다음 배당 지급일	n/a
배당락일	n/a
주당 배당금	n/a
배당 성향	n/a

최근 배당 및 자사주 매입 업데이트

업데이트 없음

Recent updates

Seeking Alpha • 12h

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Summary ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism. The Tokyo-172 BCG deal positions IBRX to resolve U.S. supply bottlenecks, enabling dual-source BCG infrastructure and global expansion, enhancing platform value. Read the full article on Seeking Alpha

분석 기사 • May 11

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...

새로운 내러티브 • Apr 01

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Mar 18

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Mar 04

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?

분석 기사 • Aug 07

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...

Seeking Alpha • Apr 29

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking Alpha

Seeking Alpha • Mar 07

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking Alpha

Seeking Alpha • Jan 17

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking Alpha

Seeking Alpha • Dec 11

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

Summary Anktiva received FDA approval in April 2024 for BCG-unresponsive NMIBC. Q3 revenue was $5.954 million, but high R&D and SG&A expenses led to an $80.253 million operational loss, with notable share dilution. Financial health shows a current ratio over 2.0, but high long-term debt and a $34 million monthly cash burn raise concerns. ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. IBRX remains a "sell" due to ongoing dilution, financial risks, and limited upside despite Anktiva's potential in NMIBC. Read the full article on Seeking Alpha

Seeking Alpha • Oct 25

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

Summary ImmunityBio's Anktiva shows promise in cancer immunotherapy, with initial sales of $900K and ongoing studies in various cancers, including non-small cell lung cancer. Despite high debt and cash burn, friendly debt terms from entities connected to the founder mitigate financial risks, maintaining shareholder value. The company's novel platforms, like the CD19 t-haNK therapy, diversify its pipeline, reducing reliance on Anktiva alone for future growth. While IBRX has significant upside potential, any negative news could deflate the stock's hype-driven valuation, making it a high-risk investment. Read the full article on Seeking Alpha

Seeking Alpha • Oct 07

ImmunityBio: Moving The Needle

Summary ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding. I plan to capitalize on the current sell-off, placing buy orders around $3.50-$4.00, and setting sell targets at $9 and $12.25 per share. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Summary Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls. Anktiva's competitive position in a diversified NMIBC market is strong, but the financial entanglement with Dr. Soon-Shiong poses significant risks for retail investors. Read the full article on Seeking Alpha

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 과거에 IBRX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: IBRX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

배당 수익률 vs 시장

ImmunityBio 배당 수익률 vs 시장

IBRX의 배당 수익률은 시장과 어떻게 비교되나요?
구분	배당 수익률
회사 (IBRX)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Biotechs)	2.4%
분석가 예측 (IBRX) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 IBRX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 IBRX 의 배당 수익률을 평가할 수 없습니다.

주주 대상 이익 배당

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 IBRX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주 현금 배당

현금 흐름 범위: IBRX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

높은 배당을 제공하는 우량 기업 찾기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/20 04:28
종가	2026/05/20 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

ImmunityBio, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Justin Zelin	BTIG
Suranjit Mukherjee	BTIG
Jason Kolbert	D. Boral Capital LLC.

ImmunityBio 배당 및 자사주 매입

배당 기준 점검 0/6

핵심 정보

최근 배당 및 자사주 매입 업데이트

Recent updates

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

ImmunityBio Extends Patent Protection for ANKTIVA Plus BCG Bladder Cancer Therapy to 2035

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

New major risk - Financial position

Forecast to breakeven in 2028

First quarter 2026 earnings released: US$0.62 loss per share (vs US$0.15 loss in 1Q 2025)

ImmunityBio, Inc., Annual General Meeting, Jun 09, 2026

ImmunityBio Announces Anktiva Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients

ImmunityBio Inc Addresses FDA Correspondence and Implements Enhanced Advertising Compliance Measures

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA Plus BCG Versus BCG Alone

ImmunityBio, Inc. Announces Approval For ANKTIVA In Macau Sar China For Bcg-Unresponsive Nmibc With Cis ± Papillary Tumors

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Immunitybio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva Plus BCG for Patients with BCG-Unresponsive NMIBC with Papillary-Only Disease

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from over 60 Healthy and Cancer Donors

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Forecast breakeven date moved forward to 2027

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

ImmunityBio, Inc. Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA®? Plus BCG Versus BCG Alone in BCG-Naive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

President exercised options and sold US$675k worth of stock

New major risk - Financial position

Full year 2025 earnings: EPS exceeds analyst expectations

ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio, Inc. Reports Productive Regulatory Engagement with Saudi Food and Drug Authority At USA -Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

President exercised options and sold US$971k worth of stock

ImmunityBio, Inc. Launches Phase 2 Chemotherapy-FreeCAR-NK Cell Therapy Trial with Anktiva (ResQ215B) in Indolent Lymphomas

ImmunityBio, Inc. Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy

Price target increased by 9.6% to US$11.40

Board Member notifies of intention to sell stock

Immunitybio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer

Consensus estimates of losses per share improve by 10%

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

New minor risk - Share price stability

Saudi Fda Grants Accelerated Approval to ImmunityBio , Inc.'s Anktiva for Non-Muscle Invasive Bladder Cancer Witharcinoma In-Situ

ImmunityBio, Inc. Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Forecast to breakeven in 2028

ImmiBio, Inc. Announces Treatment with ANKTIVA®? (nogapendekin Alfa Inbakicept-pmln) Plus Bacillus Calmette-Guerin

ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025

Immunitybio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for Anktiva with Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

New minor risk - Financial position

Third quarter 2025 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

ImmunityBio, Inc. Announces its ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio, Inc. Announces Initial Data Shows 100% Disease Control in 5 Out of 5 Patients with Recurrent Glioblastoma with Two Patients in Near Complete Response Treated with Immunotherapy's ANKTIVA®?, NK Cell Therapy Plus Optune Gio®? Device

ImmunityBio, Inc. Announces Phase 2 Study of ANKTIVA®? in Patients with Long COVID

Price target decreased by 16% to US$10.20

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free

ImmunityBio, Inc. Announces Houston's Michael E. DeBakey Department of Veterans Affairs Medical Center Is Among the First VA Hospitals to Helpister ANKTIVA to Bladder Cancer Patients

No longer forecast to breakeven

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield™ Platform, in Patients with Solid Tumors

First quarter 2025 earnings: EPS misses analyst expectations

ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application

ImmunityBio, Inc., Annual General Meeting, Jun 18, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG

New major risk - Shareholder dilution

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $75.000001 million.

Pomerantz LLP and Holzer & Holzer, LLC Announces Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio, Inc. Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching

Consensus revenue estimates decrease by 23%, EPS upgraded

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Price target decreased by 7.7% to US$11.25

New minor risk - Shareholder dilution

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ImmunityBio, Inc. Announces Certain Operational Results Following Approval of the Permanent J-Code (J9028) in January 2025

New major risk - Share price stability

ImmunityBio, Inc. Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-Of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

President exercised options and sold US$267k worth of stock

U.S. Food and Drug Administration Authorizes ImmunityBio, Inc. to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

Immunitybio, Inc. Announces Uk Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for Anktiva